UCB Announces Major U.S. Investment To Expand Biologics Manufacturing Capacity

• Committed to serve U.S. patients and deliver economic impact of approximately $5B, including creation of 300 U.S. direct high skilled jobs and more than 500 construction jobs
• Scaling up U.S. based Contract Manufacturing Organization (CMOs) partnerships to support the growth of UCB’s growth drivers
• Building on years of U.S. expansion while reinforcing UCB’s long-term commitment to innovation, sustainable healthcare, and economic contribution

UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States. The project is expected to serve UCB’s growing number of patients in the U.S., while delivering a total estimated economic impact of approximately $5B. UCB is also continuing to scale up its partnerships with U.S. CMOs to ensure the support for the production of its growth drivers and future pipeline.

UCB’s growing footprint in the United States reflects our long-term commitment to delivering scientific innovation, economic impact, and sustainable healthcare value. Since 2017, our U.S. workforce has expanded by 73% to around 2,000 employees, underpinned by $4.5B in acquisitions and capital investments that have strengthened our innovation capabilities and infrastructure. Over this time, we have achieved 15 FDA approvals or indication expansions—eight of which came in just the past two years— delivering meaningful advances in care for people living with severe diseases.

The planned U.S. manufacturing facility marks a key advancement in UCB’s strategic ambition: it brings us closer to one of our fastest-growing markets and supports a more resilient and sustainable supply chain – while ensuring our global manufacturing capacity keeps pace with our innovation pipeline and prepare for the growth that lies ahead.

“At UCB, we are guided by a clear purpose—to create value for patients now and into the future,” said UCB’s CEO Jean-Christophe Tellier. “This investment reflects our growing impact in the US and our ambition to bring our forthcoming pipeline to patients around the world. By expanding our biologics manufacturing footprint, we’re not only reinforcing our global supply chain—we’re also contributing to the vitality of biomedical innovation, high-skilled jobs, and long-term economic impact in the US.”

The new facility is expected to create around 300 permanent, highly skilled direct jobs in biologics manufacturing and more than 500 jobs during construction. UCB is currently undertaking a comprehensive feasibility study to determine the ideal U.S. location, with a focus on regions that offer strong talent pipelines and innovation ecosystems.

This latest investment will not only support future medicine delivery—it will also generate significant value across communities through increased economic activity, partnerships, and job creation.

About UCB
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1B in 2024. For more information, visit www.ucb.com